GBA1 and Parkinson disease: This has been confirmed by in vivo studies showing that PD and DLB patients carrying pathogenic GBA mutations had reduced levels of lysosomal GCase activity paralleled by lower CSF levels of total alpha-synuclein (possibly mirroring greater Lewy pathology in the brain).